These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 3756886)

  • 1. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
    Rinehart J; Malspeis L; Young D; Neidhart J
    Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma.
    Rinehart JJ; Malspeis L; Young D; Neidhart JA
    J Biol Response Mod; 1986 Aug; 5(4):300-8. PubMed ID: 3090208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.
    Kinney P; Triozzi P; Young D; Drago J; Behrens B; Wise H; Rinehart JJ
    J Clin Oncol; 1990 May; 8(5):881-5. PubMed ID: 2332772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant interferon alpha-2 (INTRON A) in a phase II study of renal cell carcinoma.
    Kempf RA; Grunberg SM; Daniels JR; Skinner DG; Venturi CL; Spiegel R; Neri R; Greiner JM; Rudnick S; Mitchell MS
    J Biol Response Mod; 1986 Feb; 5(1):27-35. PubMed ID: 3958753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Histopathologic evaluation of anti-tumor activity of alpha-interferon for renal cell carcinoma, especially in autoptic cases].
    Yamauchi T; Kawamura J; Yoshida O; Fukuyama T; Ogura K; Nakagawa K
    Hinyokika Kiyo; 1985 Sep; 31(9):1539-52. PubMed ID: 4083212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial.
    Figlin RA; deKernion JB; Maldazys J; Sarna G
    Cancer Treat Rep; 1985 Mar; 69(3):263-7. PubMed ID: 3978656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
    Whitehead RP; Ward D; Hemingway L; Hemstreet GP; Bradley E; Konrad M
    Cancer Res; 1990 Oct; 50(20):6708-15. PubMed ID: 2208137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I evaluation of a synthetic mutant of beta-interferon.
    Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
    Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
    J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of interferon-beta-serine in patients with renal cell carcinoma: immunological and biological effects.
    Rinehart JJ; Young D; Laforge J; Colborn D; Neidhart JA
    Cancer Res; 1987 May; 47(9):2481-5. PubMed ID: 3567933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of recombinant beta-interferon given by four-hour infusion.
    Grunberg SM; Kempf RA; Venturi CL; Mitchell MS
    Cancer Res; 1987 Feb; 47(4):1174-8. PubMed ID: 3802098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
    Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
    Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
    Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
    Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
    J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of human lymphoblastoid interferon in patients with advanced renal carcinoma.
    Vugrin D; Hood L; Taylor W; Laszlo J
    Cancer Treat Rep; 1985; 69(7-8):817-20. PubMed ID: 4016792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The treatment of renal cell carcinoma with recombinant human leukocyte interferon].
    Kawamura J; Yamauchi T; Hashimura T; Yoshida O; Kohnami T; Tomoyoshi T; Ogura K; Fukuyama T; Nakagawa K
    Hinyokika Kiyo; 1985 Mar; 31(3):377-86. PubMed ID: 4025077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
    Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of high-dose human lymphoblastoid alpha interferon in patients with advanced renal carcinoma.
    Vugrin D; Hood L; Laszlo J
    J Biol Response Mod; 1986 Aug; 5(4):309-12. PubMed ID: 3734846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy of renal cell carcinoma. 3. Interferon therapy].
    Kobayashi M; Imai K; Kiren H; Nakai K; Saruki K; Umeyama T; Ito Y; Yamanaka H; Makino T; Machida M
    Hinyokika Kiyo; 1987 Apr; 33(4):508-14. PubMed ID: 3618421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.